Entrada Therapeutics (TRDA) investor relations material

Platform overview and differentiation

• Endosomal Escape Vehicle (EEV) platform enables 50-fold higher cytosolic delivery of therapeutic cargo compared to standard methods, addressing key challenges in cellular uptake and endosomal escape.

• EEV conjugation significantly improves drug retention in the body and enhances delivery to muscle fibers and quiescent satellite cells, supporting muscle regeneration in DMD.

• Cyclic peptide structure and use of natural amino acids contribute to a favorable safety profile, minimizing renal toxicity and allowing for less frequent dosing.

• Dosing regimens are optimized to saturate renal clearance, increasing muscle uptake without compromising kidney safety.

Clinical program updates and data readouts

• Multiple clinical programs are advancing, with ENTR-601-44 and ENTR-601-45 targeting different DMD submutations and a partnered program with Vertex for DM1.

• Recent data from ENTR-601-44 showed strong safety and early functional benefit, with further open-label and higher-dose cohort data expected soon.

• ENTR-601-45 Cohort 1 data is anticipated in October, focusing on safety, with efficacy signals expected in subsequent cohorts.

• Dose escalation in both programs aims to demonstrate dose-dependent biomarker and functional responses, supporting regulatory and commercial positioning.

Biomarker and functional outcomes

• Early trials showed functional improvement in DMD patients with modest dystrophin increases, suggesting a potential disconnect between biomarker and clinical benefit.

• Ongoing and future cohorts are designed to confirm dose-dependent increases in dystrophin and functional outcomes, critical for accelerated approval and phase III success.

• Expansion cohorts will increase patient numbers to meet regulatory requirements, with a total of around 40 patients targeted for the accelerated approval package.